MHRA asks drugmakers for more data on API suppliers

By Gareth Macdonald

- Last updated on GMT

Related tags European union

MHRA asks MA holders for more API data
MHRA asks MA holders for more API data
The UK MHRA says regulators Europe-wide are asking drugmakers for additional data to identify plants that need to be inspected under new EU API import rules.

From July active pharmaceutical ingredients (API) shipped to the European Union will need to be accompanied written confirmation from local regulators that they were produced to standards equivalent to European good manufacturing practices (GMP).

The UK Medicines and Healthcare products Regulatory Agency (MHRA) told in-Pharmatechnologist.com it is “asking all authorised manufacturers of medicinal products for human use in the UK questions relating to imported active substances used at their authorised site​.”

It went on to say that other national authorities are asking the same questions of marketing authorisation (MA) holder based in their countries and added that drug companies in the UK have been given until January 16 to provide the requested information.

Inspections

The MHRA explained that: “The resulting active substance data set will be collated with that obtained by EMA for centrally authorised products to give a list of active substance manufacturers in third countries that may need to be inspected in order to minimise the potential risk of shortages due to the incoming rules on importation of active substances​.”

The comments come just a few weeks after the MHRA warned the new EU laws may require it to inspect as many as 1,200 API manufacturing sites​, which prompted concerns that it lacked sufficient capacity to conduct these assessments.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Webinars

Headlines